|
|
Article: Aegerion's Series A Adds $22M For Cholesterol-Lowering Work.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
In its first financing since it was founded in February 2005, Aegerion Pharmaceuticals Inc. raised $22.5 million in an oversubscribed Series A round to fund Phase II development of its lead dyslipidemia drug, AEGR 733.
Boston-based Advent International led the round, which also included investments from Geneva-based Index Ventures, San Francisco-based Alta Partners and Boston-based MVM Life Science Partners.
"We actually had more people interested in our Series A round than we had space for," said Jerry Wisler, president and CEO, attributing that interest to the growing size of the cholesterol-lowering drug market.
About ...